Vulnerable COPD patients with comorbidities: the role of roflumilast

References

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseGlobal Initiative for Chronic Obstructive Lung Disease2014 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdfAccessed August 11, 2014
   Google Scholar
• RuttenFHCramerMJGrobbeeDEUnrecognized heart failure in elderly patients with stable chronic obstructive pulmonary diseaseEur Heart J200526181887189415860516
   PubMed Web of Science ®Google Scholar
• IversenKKKjaergaardJAkkanDECHOS Lung Function Study GroupThe prognostic importance of lung function in patients admitted with heart failureEur J Heart Fail201012768569120395261
   PubMed Web of Science ®Google Scholar
• YancyCWJessupMBozkurtB2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation2013128161810185223741057
   PubMed Web of Science ®Google Scholar
• FihnSDGardinJMAbramsJAmerican College of Cardiology FoundationAmerican Heart Association Task Force on Practice GuidelinesAmerican College of Physicians2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsJ Am Coll Cardiol20126024e44e16423182125
   PubMed Web of Science ®Google Scholar
• WestfallTCWestfallDPAdrenergic agonists and antagonistsBruntonLLChabnerBAKnollmannBCGoodman & Gilman’s The Pharmacological Basis of Therapeutics12th edNew York, NYThe McGraw-Hill Companies2011277355
   Google Scholar
• SalpeterSOrmistonTSalpeterECardioselective beta-blockers for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20054CD00356616235327
   PubMed Web of Science ®Google Scholar
• MainguyVGirardDMaltaisFEffect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary diseaseAm J Cardiol2012110225826322497677
   PubMed Web of Science ®Google Scholar
• StefanMSRothbergMBPriyaAPekowPSAuDHLindenauerPKAssociation between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertensionThorax2012671197798422941975
   PubMed Web of Science ®Google Scholar
• MadsenHBrixenKHallasJScreening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population-based database studyClin Respir J201041222920298414
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
   PubMed Web of Science ®Google Scholar
• FergusonGTCalverleyPMAndersonJAPrevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health studyChest200913661456146519581353
   PubMed Web of Science ®Google Scholar
• PauwelsRALöfdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• DecramerMLacquetLMFagardRRogiersPCorticosteroids contribute to muscle weakness in chronic airflow obstructionAm J Respir Crit Care Med1994150111168025735
   PubMed Web of Science ®Google Scholar
• DecramerMde BockVDomRFunctional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19961536 Pt 1195819648665061
   PubMed Web of Science ®Google Scholar
• Daliresp^® (roflumilast) tablets [prescribing information]OranienburgNycomed GmbH2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022522s000lbl.pdfAccessed August 11, 2014
   Google Scholar
• RabeKFUpdate on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseBr J Pharmacol20111631536721232047
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMBredenbrokerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPDRespir Res2011121821272339
   PubMed Web of Science ®Google Scholar
• HermannRNassrNLahuGSteady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosisClin Pharmacokinet200746540341617465639
   PubMed Web of Science ®Google Scholar
• BethkeTDHartmannMHünnemeyerALahuGGleiterCHInfluence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center studyInt J Clin Pharmacol Ther201149849149921781649
   PubMed Web of Science ®Google Scholar
• PageCPSpinaDSelective PDE inhibitors as novel treatments for respiratory diseasesCurr Opin Pharmacol201212327528622497841
   PubMed Web of Science ®Google Scholar
• HatzelmannAMorcilloEJLungarellaGThe preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulm Pharmacol Ther201023423525620381629
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSAVerhooselRMReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax200762121081108717573446
   PubMed Web of Science ®Google Scholar
• HohlfeldJMSchoenfeldKLavae-MokhtariMRoflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trialPulm Pharmacol Ther200821461662318374614
   PubMed Web of Science ®Google Scholar
• HaunsBHermannRHünnemeyerAInvestigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjectsJ Clin Pharmacol200646101146115316988203
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellDWitteSBredenbrökerDBethkeTDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet2005366948556357116099292
   PubMed Web of Science ®Google Scholar
• CalverleyPMSanchez-TorilFMcIvorATeichmannPBredenbroekerDFabbriLMEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007176215416117463412
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJM2-124 and M2-125 study groupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLM2-127 and M2-128 study groupsRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• BatemanEDRabeKFCalverleyPMRoflumilast with long-acting β2-agonists for COPD: influence of exacerbation historyEur Respir J201138355356021737553
   PubMed Web of Science ®Google Scholar
• LeeSDHuiDSMahayiddinAARoflumilast in Asian patients with COPD: a randomized placebo-controlled trialRespirology20111681249125721848706
   PubMed Web of Science ®Google Scholar
• ZhengJYangJZhouXRoflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group studyChest20141451445224135893
   PubMed Web of Science ®Google Scholar
• ObaYLoneNAEfficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisTher Adv Respir Dis201371132423197074
   PubMed Web of Science ®Google Scholar
• CalverleyPMMartinezFJFabbriLMGoehringUMRabeKFDoes roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolInt J Chron Obstruct Pulmon Dis2012737538222791991
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMPvan NootenFELindemannMCaeserMCalverleyPMA 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary diseasePharmacoeconomics200725869571117640111
   PubMed Web of Science ®Google Scholar
• HertelNKotchieRWSamyshkinYRadfordMHumphreysSJamesonKCost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysisInt J Chron Obstruct Pulmon Dis2012718319922500119
   PubMed Web of Science ®Google Scholar
• SamyshkinYKotchieRWMörkACBriggsAHBatemanEDCost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United KingdomEur J Health Econ2014151698223392624
   PubMed Web of Science ®Google Scholar
• PereraPNArmstrongEPSherrillDLSkrepnekGHAcute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortalityCOPD20129213114122409371
   PubMedGoogle Scholar
• Red Book Online2013 Available from: http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/redbook.ModifyRedBookSearchAccessed August 11, 2014
   Google Scholar